# Treatment Approach for Advanced Systemic Light Chain Amyloidosis: A Case Report

## TL;DR

A 62-year-old patient with advanced systemic light chain amyloidosis showed significant improvement after treatment with a regimen including daratumumab.

## Contribution

The successful integration of daratumumab in treating advanced systemic light chain amyloidosis is highlighted as a potential new treatment approach.

## Key findings

- The patient's condition improved from stage IV to stage II according to NCCC guidelines.
- Treatment with cyclophosphamide, bortezomib, dexamethasone, and daratumumab led to significant improvements in multiple organ systems.
- The case underscores the potential of daratumumab as a valuable addition to treatment regimens for this condition.

## Abstract

Systemic light chain amyloidosis is a rare and severe disorder characterized by amyloid fibril deposition in various tissues, often leading to organ failure. Early diagnosis is crucial but challenging due to diverse clinical manifestations. Our case report presents a complex case of systemic light chain amyloidosis in a 62-year-old patient with cardiac, renal, neurological, and gastrointestinal involvement. The patient's treatment with cyclophosphamide, bortezomib, dexamethasone, and intravenous daratumumab yielded significant improvement, aligning with recent studies. Following treatment, the patient improved from stage IV to stage II systemic light chain amyloidosis per the National Comprehensive Cancer Network (NCCN) guidelines, indicating a more favorable prognosis. Hence, the successful integration of daratumumab in our case underscores its potential as a valuable addition to the treatment regimen for advanced systemic light chain amyloidosis, showcasing significant improvements across multiple organ systems.